B. Claims

Please amend claims 17-18 as follows. The following is a complete listing of the claims in this application and replaces all earlier versions and all earlier listings of the claims.

1. (Previously Presented) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R_1, R_2, R_3, R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2-C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C_1-C_4 alkyl group;

W is CO_2H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

2. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

2-{[(2,4-dichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-{[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-5-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-methyl-5-nitrophenoxy)acetyl]amino}benzoic acid;

2-{[(2-fluoro-5-methylphenoxy)acetyl]amino}benzoic acid;

2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;

2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;

2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}benzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2S)-2-(4-chlorophenoxy)propanoyl]amino}benzoic acid;

2-{[(2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2,4-dibromophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chlorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(3-bromophenyl)glycyl]amino}benzoic acid;

2-{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl}amino}benzoic acid;

2-{[(4-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(5-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(3,4-difluorophenoxy)acetyl]amino}benzoic acid;

2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;

2-{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;

2-{[(2-cyanophenoxy)acetyl]amino}benzoic acid;

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chloro-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-({[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino)benzoic acid;

2-{[(2-ethyl-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-({[(3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;

2-({[(4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;

2-{[(2-bromo-4,5-difluorophenoxy)acetyl]amino}benzoic acid;

2-({[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2,4,5-trifluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3,5-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-({[(2,4,5-trichlorophenyl)thio]acetyl}amino)benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;

2-{[(3,5-difluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3,5-difluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chloro-6-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(4-chloro-3-ethylphenoxy)acetyl]amino}benzoic acid;

2-{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

5-hydroxy-2-{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

2-{[(3-chloro-4-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(3-chloro-4-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3 -chloro-4-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;

2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2-fluoro-4-methylphenyl)glycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2,5-dichlorophenyl)glycyl]amino}benzoic acid;

2-{[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3-chloro-4-fluorophenyl)glycyl]amino}benzoic acid;

2-{[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromo-4-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[2-(2-chloro-phenoxy)acetyl]amino}benzoic acid;

2-[{(4-bromophenyl)methyl}{2-isopropyl-5-methylphenoxyacetyl}amino]benzoic acid;

2-{[(4-cyclohexylphenoxy)acetyl]amino}benzoic acid; and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

4. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 1 wherein the mammal is human.

6. (Original) The method of claim 5 wherein the composition is administered orally to said human.

7. (Original) The method of claim 6 wherein the compound is administered orally at a dose range of about 0.01 to 100 mg/kg from 1 to 6 times a day.

8. (Original) The method of claim 7 wherein the compound is administered orally at a dose range of about 0.1 to 10 mg/kg from 1 to 6 times a day.

9. (Original) The method of claim 8 wherein the compound is administered from 1 to 4 times a day.

10. (Original) The method of claim 5 wherein the composition is administered subcutaneously to said human.

11. (Previously Presented) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R_1, R_2, R_3, R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2-C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C_1-C_4 alkyl group;

W is CO_2H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen;

and a pharmaceutically acceptable carrier.

12. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

2-{[(2,4-dichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-{[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-5-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-methyl-5-nitrophenoxy)acetyl]amino}benzoic acid;

2-{[(2-fluoro-5-methylphenoxy)acetyl]amino}benzoic acid;

2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;

2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;

2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;

2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}benzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;

2-{[(3-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2S)-2-(4-chlorophenoxy)propanoyl]amino}benzoic acid;

2-{[(2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2,4-dibromophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chlorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(3-bromophenyl)glycyl]amino}benzoic acid;

2-{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl}amino}benzoic acid;

2-{[(4-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(5-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(3,4-difluorophenoxy)acetyl]amino}benzoic acid;

2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;

2-{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;

2-{[(2-cyanophenoxy)acetyl]amino}benzoic acid;

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chloro-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-({[4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino)benzoic acid;

2-{[(2-ethyl-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-({[(3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;

2-({[(4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;

2-{[(2-bromo-4,5-difluorophenoxy)acetyl]amino}benzoic acid;

2-({[3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2,4,5-trifluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3,5-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-({[(2,4,5-trichlorophenyl)thio]acetyl}amino)benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;

2-{[(3,5-difluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3,5-difluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chloro-6-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(4-chloro-3-ethylphenoxy)acetyl]amino}benzoic acid;

2-{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

5-hydroxy-2-{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;

2-{[(3-chloro-4-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(3-chloro-4-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-chloro-5-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(3 -chloro-4-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;

2-{[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2-fluoro-4-methylphenyl)glycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2,5-dichlorophenyl)glycyl]amino}benzoic acid;

2-{[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}benzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3-chloro-4-fluorophenyl)glycyl]amino}benzoic acid;

2-{[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromo-4-methylphenoxy)acetyl]amino}benzoic acid;

2-{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[2-(2-chloro-phenoxy)acetyl]amino}benzoic acid;

2-[{(4-bromophenyl)methyl}{2-isopropyl-5-methylphenoxyacetyl}amino]benzoic acid;

2-{[(4-cyclohexylphenoxy)acetyl]amino}benzoic acid, and pharmaceutically acceptable salts thereof.

13. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

and pharmaceutically acceptable salts thereof.

14. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

15. (Original) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R_1, R_2, R_3, R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2-C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C_1-C_4 alkyl group;

Y is CO_2H or CO_2CH_3;

Z is hydrogen or mono-methyl;

G_1 is OH, F, methoxy or hydrogen; and

G_2 is either OH, Cl, methoxy or hydrogen.

16. (Original) The method of claim 15 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;

2-{[(3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.

17. (Currently Amended) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



(II)

and pharmaceutically acceptable salts thereof, wherein:

R_1, R_2, R_3, R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2-C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C_1-C_4 alkyl group;

Y is CO_2H ~~or CO_2CH_3~~;

Z is hydrogen or mono-methyl;

G_1 is OH, F, methoxy or hydrogen; and

G_2 is either OH, Cl, methoxy or hydrogen;

and a pharmaceutically acceptable carrier.

18. (Currently Amended) The pharmaceutical composition of claim 17 wherein the compound is selected from the group consisting of

~~2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;~~

~~2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;~~

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;

2-{[(3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;

2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and

pharmaceutically acceptable salts thereof.